Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1846 to 1860 of 8966 results

  1. Levodopa inhaled for patients with Parkinson's disease who experience 'off' episodes (motor response fluctuations) [TSID8778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Vedolizumab for treating moderately to severely active Crohn's disease in people 2 to 17 years [TSID12312]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Galcanezumab for migraine [TSID10663]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Transverse Tibial Transport

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. AHEAD implants for external ear prosthesis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  10. Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [TSID12354]

    Awaiting development Reference number: GID-TA11976 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748]

    Awaiting development Reference number: GID-TA11981 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pharmalgen for the treatment of bee and wasp venom allergy

    In development Reference number: GID-TA11898 Expected publication date: TBC

    Technology appraisal guidance
    In development